Similar articles

• Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomised, double-blind, non-inferiority trial.

  Eriksson BI, Dahl OE, Rosencher N, Kurth AA, van Dijk CN, Frostick SP, Prins MH, Hettiarachchi R, Hantel S, Schnee J, Büller HR; RE-NOVATE Study Group. Eriksson BI, et al. Lancet. 2007 Sep 15;370(9591):949-56. doi: 10.1016/S0140-6736(07)61445-7. Lancet. 2007. PMID: 17869635 Clinical Trial.
• Prevention of thromboembolic disease after non-cemented hip arthroplasty. A multimodal approach.

  Leali A, Fetto J, Moroz A. Leali A, et al. Acta Orthop Belg. 2002 Apr;68(2):128-34. Acta Orthop Belg. 2002. PMID: 12050997 Clinical Trial.
• Oral dabigatran versus enoxaparin for thromboprophylaxis after primary total hip arthroplasty (RE-NOVATE II*). A randomised, double-blind, non-inferiority trial.

  Eriksson BI, Dahl OE, Huo MH, Kurth AA, Hantel S, Hermansson K, Schnee JM, Friedman RJ; RE-NOVATE II Study Group. Eriksson BI, et al. Thromb Haemost. 2011 Apr;105(4):721-9. doi: 10.1160/TH10-10-0679. Epub 2011 Jan 12. Thromb Haemost. 2011. PMID: 21225098 Clinical Trial.
• Risk of post-discharge venous thromboembolism in patients with rheumatoid arthritis undergoing knee or hip arthroplasty. Is prolonged thromboprophylaxis warranted or dangerous?

  Nurmohamed MT, Lems WF, Dijkmans BA. Nurmohamed MT, et al. Ann Rheum Dis. 1999 Jul;58(7):392-5. doi: 10.1136/ard.58.7.392. Ann Rheum Dis. 1999. PMID: 10381480 Free PMC article. Review. No abstract available.
• Rivaroxaban for the prevention of venous thromboembolism: a single technology appraisal.

  Stevenson M, Scope A, Holmes M, Rees A, Kaltenthaler E. Stevenson M, et al. Health Technol Assess. 2009 Oct;13 Suppl 3:43-8. doi: 10.3310/hta13suppl3/07. Health Technol Assess. 2009. PMID: 19846028 Review.